EU regulator recommends approval to expand Sogroya label

Novo Nordisk said the European Union's drug regulator recommended approval of its Sogroya growth-hormone treatment for children with unexplained shortness, widening the medicine's current label. The Danish drugmaker said Friday that the European Medicines Agency's human-drugs committee issued the recommendation.